Compare · NVO vs SNPX
NVO vs SNPX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Synaptogenix Inc. (SNPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SNPX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 3726.3x SNPX ($50.3M).
- Over the past year, NVO is down 41.7% and SNPX is up 851.5% - SNPX leads by 893.2 points.
- NVO has hit the wire 11 times in the past 4 weeks while SNPX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for SNPX).
- Company
- Novo Nordisk A/S
- Synaptogenix Inc.
- Price
- $42.01-2.10%
- $24.74+1.83%
- Market cap
- $187.53B
- $50.3M
- 1M return
- -5.38%
- -10.98%
- 1Y return
- -41.69%
- +851.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Synaptogenix Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest SNPX
- SEC Form DEF 14A filed by Synaptogenix Inc.
- Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)
- Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)
- Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)
- Director Schechter Jonathan was granted 21,575 shares and covered exercise/tax liability with 8,630 shares, increasing direct ownership by 1,188% to 14,035 units (SEC Form 4)
- Director Bernstein Bruce covered exercise/tax liability with 9,863 shares and was granted 24,657 shares, increasing direct ownership by 1,341% to 15,897 units (SEC Form 4)
- Chief Medical Officer Tuchman Alan J was granted 4,315 shares and covered exercise/tax liability with 1,726 shares, increasing direct ownership by 196% to 3,909 units (SEC Form 4)
- TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
- SEC Form PRE 14A filed by Synaptogenix Inc.
- Synaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits